Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259273 | 0.86 | PTGDR2 (0.41) | MAPTTP53PTGDR2AKR1B1 | |
| SCHEMBL4254336 | 0.85 | ALDH1A1 (0.51) | MAPTTP53ALDH1A1SCN9ATHRB | |
| SCHEMBL4262828 | 0.85 | AKR1B1 (0.46) | PTGDR2AKR1B1 | |
| SCHEMBL10802626 | 0.81 | APAF1 (0.48) | MAPTTP53ALDH1A1SCN9AITGA4 | |
| SCHEMBL4172070 | 0.79 | SCN9A (0.44) | MAPTTP53ALDH1A1SCN9ATHRB | |
| SCHEMBL10955719 | 0.78 | SCN9A (0.41) | MAPTTP53ALDH1A1SCN9AITGA4 | |
| SCHEMBL10954920 | 0.77 | ALPL (0.41) | TP53ALDH1A1SCN9AITGA4ALPL | |
| SCHEMBL4159522 | 0.75 | SCN9A (0.40) | MAPTTP53ALDH1A1SCN9AITGA4 | |
| SCHEMBL4259885 | 0.74 | ADAMTS5 (0.52) | MAPTTP53ALDH1A1NPSR1SMN1; SMN2 | |
| SCHEMBL4253018 | 0.74 | AKR1B1 (0.60) | MAPTALDH1A1SCN9AITGA4AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | claimed |
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | ASTRAZENECA AB (SE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176851-A1 | Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 | TRPV1, TRPV2, TRPV3 | MAPT 3349/4885TP53 3194/4885GFER 2518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.